Breaking News
October 17, 2018 - FDA Approves Liletta (levonorgestrel-releasing intrauterine system) 52 mg to Prevent Pregnancy for up to Five Years
October 17, 2018 - Weight gain after smoking cessation linked to increased short-term diabetes risk
October 17, 2018 - Researchers find opportunity to control salt-sensitive hypertension without exercising
October 17, 2018 - Modeling Non-Numerical Data in Systems Biology
October 17, 2018 - Research aims to address health disparities in African-American men
October 17, 2018 - Human and cattle decoys trap outdoor-biting mosquitoes in malaria endemic regions
October 17, 2018 - High Circulating Prolactin Level Inversely Linked to T2DM Risk
October 17, 2018 - Study finds gene variant predisposes people to both Type 2 diabetes and low body weight
October 17, 2018 - Metrohm software products make it easy to comply with ALOCA and ALCOA+ guidelines
October 17, 2018 - Network of doctors identify the cause of 31 new conditions
October 17, 2018 - Notable improvement in brain cancer survival among younger patients but not much for elderly
October 17, 2018 - Scientists shed light on roles of transcription factors, TP63 and SOX2, in squamous cell carcinoma
October 17, 2018 - Costs of Medicare Diabetes Prevention Program may be higher than expected reimbursement
October 17, 2018 - Misuse of prescription opioids or benzodiazepines associated with suicidal thoughts
October 17, 2018 - New research seeks to address sex disparities in women’s health
October 17, 2018 - C-Section Rates Have Nearly Doubled Since 2000: Study
October 17, 2018 - Talking to Your Kids About STDs
October 17, 2018 - New classification of periodontal and peri-implant diseases and conditions
October 17, 2018 - Herbert D. Kleber, Pioneer in Addiction Treatment, Dies at 84
October 17, 2018 - Health effects of smoke-filled atmosphere
October 17, 2018 - Down syndrome may hold important clues to onset of Alzheimer’s disease
October 17, 2018 - A special report on US’ aging societies
October 17, 2018 - Birth mode may have acute effects on neurodevelopment, study suggests
October 17, 2018 - Global health innovation system fails to deliver affordable treatments to patients, says report
October 17, 2018 - Simple, inexpensive test quickly detects antibiotic-resistant ‘superbugs’
October 17, 2018 - New drugs could reduce risk of heart disease when added to statins
October 17, 2018 - Visible and valued: Stanford Medicine’s first-ever LGBTQ+ Forum
October 17, 2018 - HVP vaccination not linked with rise in teen risky sex
October 17, 2018 - Potential ‘early warning markers’ for sepsis discovered
October 17, 2018 - Who knew? Life begins (again) at 65
October 17, 2018 - Application of blood pressure guidelines ups treatment
October 17, 2018 - Stanford researchers find that small molecule may help treat enzyme deficiency
October 17, 2018 - Speed Cameras Save Money and Lives in New York City
October 17, 2018 - Men who conform to ‘the man box’ more likely to consider suicide and violence
October 17, 2018 - Researchers aim to create more authentic organoids for drug testing, transplantation
October 16, 2018 - New blood test for pediatric brain tumor patients offers safer approach than surgical biopsies
October 16, 2018 - Age-related estrogen increase may be the culprit behind inguinal hernias in men
October 16, 2018 - Skills-Based Intervention Did Not Cut Systolic BP After Stroke, TIA
October 16, 2018 - Researchers uncover new role of TIP60 protein in controlling tumour formation
October 16, 2018 - Behind the scenes of a lifesaving heart surgery
October 16, 2018 - ‘To See the Suffering’
October 16, 2018 - Drinking concentrated rosemary extract can boost memory by up to 15%, shows research
October 16, 2018 - Medicare Advantage riding high as new insurers flock to sell to seniors
October 16, 2018 - NHS tackles prescription fraud to save millions
October 16, 2018 - New molecular switch may help develop sophisticated photomedications
October 16, 2018 - Improving access to behavioral health screenings for pregnant and postpartum women
October 16, 2018 - Health Highlights: Oct. 12, 2018
October 16, 2018 - Study holds promise for new pediatric brain tumor treatment
October 16, 2018 - Patient advocate uses MRI scans to create art and spark conversations about life with illness
October 16, 2018 - Fish oil based diets may suppress growth and spread of breast cancer cells
October 16, 2018 - Number of VHA facilities offering acupuncture has increased rapidly
October 16, 2018 - Influential Leapfrog Group jumps in to rate 5,600 surgery centers
October 16, 2018 - HIV-infected infants more likely to acquire congenital cytomegalovirus infection
October 16, 2018 - Study pinpoints new marker that can predict Crohn’s disease subtype
October 16, 2018 - Simple procedure could be efficacious intervention for failed back surgery
October 16, 2018 - New research identifies modifiable dementia risk factor in elderly people
October 16, 2018 - Zebrafish study uncovers molecular ‘brake’ that helps control eye lens development
October 16, 2018 - Overlapping copy number variations underlie autism and schizophrenia in Japanese patients
October 16, 2018 - Early menopause and diabetes may reduce life expectancy
October 16, 2018 - Majority of Americans’ ancestry can be traced through existing DNA databases
October 16, 2018 - Patients coerced into mental health care less likely to perceive treatment as effective
October 16, 2018 - Healthy elders can consume walnuts without having negative impact on weight gain, finds study
October 16, 2018 - Interactive robot helps older people exercise and detects underlying health problems
October 16, 2018 - What you need to know about autism spectrum disorder
October 16, 2018 - Antidepressants can be used to treat Alzheimer’s disease
October 16, 2018 - Study uncovers important role of PRMT1 in dilated cardiomyopathy
October 16, 2018 - Nutritional quality of breakfast linked to cardiovascular and metabolic risk factors in children
October 16, 2018 - Study uses novel approach to investigate genetic origins of mental illnesses
October 16, 2018 - Scientists develop dual anthrax-plague vaccine
October 16, 2018 - Poor Outcomes for Hispanic Infants With Congenital Heart Dz
October 16, 2018 - Global study finds youngest in class more likely to be diagnosed with ADHD
October 16, 2018 - Researchers sequence two selfish genes in the fungus Neurospora intermedia
October 16, 2018 - Survey results highlight the need for better communication between patients and HCPs about bacterial vaginosis
October 16, 2018 - Researchers develop fibrin-targeting immunotherapy to protect against neurodegeneration
October 16, 2018 - Researchers create open access database on healthy immunity
October 16, 2018 - Rice University chemist wins big award to study small surfaces
October 16, 2018 - Study finds 43% drop in stroke rate
October 16, 2018 - Researchers identify basic relationships of cell cycle and cellular senescence in the placenta
October 16, 2018 - UA professor receives NSF grant to develop antifouling materials for medical implants
October 16, 2018 - Obesity Doubles Odds for Colon Cancer in Younger Women
FDA Approves Accelerated 7-Day Vaccine Dosing Schedule for Ixiaro

FDA Approves Accelerated 7-Day Vaccine Dosing Schedule for Ixiaro

image_pdfDownload PDFimage_print

GAITHERSBURG, Md.–(BUSINESS WIRE) October 05, 2018 –Valneva USA, the U.S. subsidiary of global vaccine biotech company Valneva SE, today announced U.S. Food and Drug Administration (FDA) approval of an accelerated dosing regimen for Ixiaro (Japanese Encephalitis Vaccine, Inactivated, Adsorbed), the only vaccine approved in the United States indicated for protection against disease caused by Japanese encephalitis (JE) virus.

Japanese encephalitis – a rare but serious disease and the most common form of vaccine-preventable encephalitis and viral-induced neurologic disability in Asia – is endemic to 24 countries in Asia and parts of the Western Pacific.i For effective protection from JE virus, adults aged 18 to 65 years may now receive two separate doses of Ixiaro seven days apart. Previously, the time between doses for this age group was 28 days. The standard 28-day schedule still applies to children two months to 17 years and adults 66 years and older; adults aged 18 to 65 years may also follow this schedule. The accelerated and the standard dosing schedules must be completed at least seven days before travel to endemic areas.

“The FDA approval of this accelerated 7-day dosing schedule is a positive step toward protecting more people from JE,” said Charles Daily, Valneva General Manager, U.S. “For travelers who do seek protection with a vaccine prior to travel, oftentimes they are not aware of the dosing schedule and therefore have not visited their doctor soon enough to allow for two doses. Eliminating this time barrier will make it easier for patients to plan for their travel health needs and to better protect themselves.”

A recent survey found that 72 percent of U.S. adults who traveled to Asia for 10 or more days reported visiting at least one area, or participating in an activity, that put them at increased risk for exposure to JEii virus and, based on guidelinesiii, should consider a vaccine along with other protective measures. However, the same survey found that more than one-third began preparing for travel less than a month before departure.

“I encourage anyone planning international travel to visit a travel health practitioner well in advance of their anticipated departure date to learn about preventative measures for travel-related diseases,” said Dr. Scott Morcott, family physician and Medical Director of Passport Health Chicago. “For those whose travel plans change unexpectedly, this shorter vaccine dosing regimen may help to protect them in less time.”

According to the World Health Organization, JE is endemic to 24 countries across Asia and parts of the western Pacific. While most people infected with JE virus – which is transmitted by mosquitoes – are asymptomatic or experience only mild symptomsiv, it can be fatal or cause long-term serious complications. There is no specific treatment for JE, and the Centers for Disease Control and Prevention (CDC) recommends that, in addition to personal protective measures, travelers who spend 30 days or more in a JE-endemic region be vaccinated prior to arrival. In addition, shorter-term travelers should consider vaccination if their activities or location put them at risk for a mosquito bite.

About the Survey

The survey of 776 adults (18+) from across the United States was conducted in May-June 2018 to better understand the awareness and knowledge of health risks related to international travel. Of those queried, 514 participants had traveled to Asia for 10-29 days within the past 24 months, and 262 participants had traveled for 30 or more days.

About Ixiaro

Valneva is the manufacturer of Ixiaro, a vaccine indicated for the prevention of disease caused by JE virus, approved for use in individuals two months of age and older.

For adults aged 18 to 65, the vaccine is given in two doses, seven days apart (accelerated schedule) or 28 days apart (standard schedule), and vaccination should be completed seven days prior to potential exposure to JE virus.

For pediatric (two months to <18 years) and older adult (66+ years) travelers, the vaccine is given in two doses, 28 days apart (standard schedule), and vaccination should be completed seven days prior to potential exposure to JE virus.

About Japanese Encephalitis

JE is a deadly infectious disease that is endemic to 24 countries across Asia, Southeast Asia, and the western Pacific. About 68,000 cases of JE are estimated to occur each year, although the actual number of cases is likely much higher due to underreporting in rural areas. JE is fatal in up to 30 percent of those who show symptoms, and up to half of survivors continue to have neurologic, cognitive, and psychiatric impairment. In 2005, JE killed more than 1,200 children in only one month during an epidemic outbreak in Uttar Pradesh, India, and Nepal.

According to the CDCv, the risk of JE is low for most travelers to Asia but can vary based on various factors, such as where a person spends time, when and for how long they are traveling and their activities. Travelers staying one month or longer (for example, military members and their families, study abroad students, or employees with extended work assignments) in parts of Asia where the JE virus is found are recommended for vaccination. Vaccination should be considered for travelers who have an increased risk of being exposed to mosquitoes carrying JE virus if they spend substantial time outdoors or in rural areas, especially at night; participate in extensive active outdoor activities such as camping, hiking, biking, fishing, or hunting, or sleep in accommodations without mosquito nets; or whose plans are uncertain or may change. JE vaccine is not recommended for short-term travel restricted to urban areas or outside of the JE virus transmission season.

For more information about JE and Ixiaro, or for the full prescribing information, visit www.PreventJE.com.

About Valneva USA, Inc.

Valneva USA, Inc. is a subsidiary of Valneva SE, a fully integrated, commercial stage biotech company focused on developing innovative life-saving vaccines.

Valneva USA is focused on the marketing and distribution of Valneva’s vaccines, including Ixiaro, in the United States. For more information, follow Valneva on Twitter @ValnevaUSA or on Facebook.

i World Health Organization. Japanese encephalitis Fact sheet no.386. December 2015. http://www.who.int/mediacentre/factsheets/fs386/en. Accessed October 1, 2018.

ii Data on file.

iii Centers for Disease Control and Prevention. Japanese encephalitis. Updated August 2015. https://www.cdc.gov/japaneseencephalitis/. Accessed October 1, 2018.

iv World Health Organization. Japanese encephalitis Fact sheet no.386. December 2015. http://www.who.int/mediacentre/factsheets/fs386/en. October 1, 2018.

v Prevention, C. (2018). Japanese Encephalitis – Chapter 3 – 2018 Yellow Book | Travelers’ Health | CDC. [online] wwwnc.cdc.gov. Available at: https://wwwnc.cdc.gov/travel/yellowbook/2018/infectious-diseases-related-to-travel/japanese-encephalitis [Accessed October 1, 2018].

Source: Valneva USA

Posted: October 2018

Related Articles:

Ixiaro (Japanese Encephalitis Virus Vaccine, Inactivated, Adsorbed) FDA Approval History

Tagged with:

About author

Related Articles